You are here:

entecavir (Baraclude)


following a full submission

entecavir (Baraclude®) is not recommended for use within NHS Scotland.

Indication under review: treatment of chronic hepatitis B virus (HBV) infection in adults with decompensated liver disease.

Entecavir demonstrated a superior virological response in adults with chronic HBV and decompensated liver disease compared with another nucleoside/nucleotide analogue. However there is no comparative evidence versus the relevant comparator.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: entecavir (Baraclude)
SMC Drug ID: 747/11
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: Treatment of chronic hepatitis B infection in adults with decompensated liver disease
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 16 January 2012